Seattle Researchers Kick Off $95 Million AI-Biology Initiative Amid Major Biotech Setbacks
Scientists in Seattle have launched a $95 million program that uses artificial intelligence to advance biology, announced alongside Ultragenyx's Phase 3 failure in Angelman syndrome and a new AI accelerator from David Baker.
Why it matters
The funding could accelerate AI-driven breakthroughs in medicine while highlighting the risks biotech firms face.
In this story
AI biology$95 millionPhase 3 failureAngelman syndromeDavid BakeracceleratorbiotechSeattle scientists
